BetterScholar BetterScholar
12
Role
Title
Level Year L/R
🐜 Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
24 auth. K. Conlon, E. Lugli, H. Welles, H. Welles, S. Rosenberg, A. Fojo, J. Morris, T. Fleisher, S. Dubois, L. Perera, ... D. Stewart, C. Goldman, B. Bryant, J. Decker, Jing Chen, T. Worthy, W. Figg, C. Peer, M. Sneller, H. Lane, J. Yovandich, S. Creekmore, M. Roederer, T. Waldmann
9 2015
9
🐜
🐜 Expression of interleukin 2 receptors on activated human B cells
9 auth. T. Waldmann, C. Goldman, R. Robb, J. Depper, W. Leonard, S. Sharrow, ... K. Bongiovanni, S. Korsmeyer, W. Greene
8 1984
8
🐜
🐜 The Sézary syndrome: a malignant proliferation of helper T cells.
9 auth. S. Broder, R. Edelson, M. Lutzner, D. Nelson, R. Macdermott, M. Durm, ... C. Goldman, B. Meade, T. Waldmann
8 1976
8
🐜
🐜 The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.
9 auth. R. Bamford, Angus J. GRANTt, J. Burton, C. Peters, G. Kurys, C. Goldman, ... Jennifer A. Brennan, E. Roessler, T. Waldmann
8 1994
8
🐜
🐜 A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.
9 auth. J. Burton, R. Bamford, C. Peters, Angus J. GRANTt, G. Kurys, C. Goldman, ... Jennifer A. Brennan, E. Roessler, T. Waldmann
8 1994
8
🐜
🐬 Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.
M. Tsudo, R. Kozak, C. Goldman, T. Waldmann
8 1986
8
🐬
🐜 Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells.
8 auth. S. Broder, R. Humphrey, Mary Durm, M. Blackman, B. Meade, C. Goldman, ... W. Strober, T. Waldmann
8 1975
8
🐜
🐜 Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.
11 auth. R. Nussenblatt, E. Fortin, R. Schiffman, L. Rizzo, Janine A. Smith, P. V. Veldhuisen, ... P. Sran, Anita Yaffe, C. Goldman, T. Waldmann, S. Whitcup
8 1999
8
🐜
🐜 Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.
23 auth. T. Waldmann, J. D. White, J. Carrasquillo, J. Reynolds, C. Paik, O. Gansow, M. Brechbiel, E. Jaffe, T. Fleisher, C. Goldman, ... L. Top, R. Bamford, E. Zaknoen, E. Roessler, C. Kasten‐SportΓ¨s, R. England, H. Litou, J. Johnson, T. Jackson-White, A. Manns, B. Hanchard, R. Junghans, D. Nelson
7 1995
7
🐜
🐜 The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.
8 auth. Mitsuru Tsudo, C. Goldman, K. Bongiovanni, Wing C. Chan, Elliott F. Winton, Masato Yagita, ... Elizabeth A. Grimm, Thomas A. Waldmann
7 1987
7
🐜
🐜 Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor.
10 auth. T. Waldmann, W. Greene, P. Sarin, C. Saxinger, D. Blayney, W. Blattner, ... C. Goldman, K. Bongiovanni, S. Sharrow, J. Depper
7 1984
7
🐜
🐜 Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
18 auth. Thomas A. Waldmann, E. Lugli, M. Roederer, L. Perera, Jeremy V. Smedley, Rhonda P. Macallister, C. Goldman, B. Bryant, Jean M. Decker, T. A. Fleisher, ... H. Clifford Lane, M. Sneller, Roger J. Kurlander, D. Kleiner, John M. Pletcher, William D. Figg, J. Yovandich, S. Creekmore
7 2011
7
🐜